Investor Relations

Company Announcements

Load More

In the News

Load More

Corporate
Investor Deck

View The Deck >

Investor Relations

X (Twitter)

ImmVirX Follow

ImmVirX
immvirx ImmVirX @immvirx ·
6 Nov

CEO Dr Malcolm McColl joined the Phase III podcast to discuss ImmVirX’s oncolytic virus platform and its lead asset IVX037. Dr McColl describes IVX037’s mode of action, encouraging early clinical data and interest from pharma groups

Listen at: https://buff.ly/4fkiHsU

Reply on Twitter 1854103703998886024 Retweet on Twitter 1854103703998886024 1 Like on Twitter 1854103703998886024 1 Twitter 1854103703998886024
immvirx ImmVirX @immvirx ·
28 Oct

ImmVirX today announced that the first 2 patients have been dosed in its CP-IVX001 Phase 1b trial: https://buff.ly/3AeZY2t

The trial will evaluate IVX037 & Innovent Bio’s anti-PD-1 inhibitor TYVYT® (sintilimab) in patients with late stage colorectal, gastric and ovarian cancer.

Reply on Twitter 1850750177298051370 Retweet on Twitter 1850750177298051370 1 Like on Twitter 1850750177298051370 1 Twitter 1850750177298051370
immvirx ImmVirX @immvirx ·
19 Sep

ImmVirX hosted an investor/clinician presentation event at Western Sydney University.

Our CEO Dr Malcolm McColl & CSO Prof Darren Shafren presented on our lead drug candidate IVX037, including promising Phase 1 Data, next steps, site expansion plans & upcoming catalysts.

4

Reply on Twitter 1836626670138118536 Retweet on Twitter 1836626670138118536 1 Like on Twitter 1836626670138118536 1 Twitter 1836626670138118536
Load More

Join Our Mailing List

Our mission is to improve outcomes for patients with cancers in which immunotherapy treatments have limited effect

About Us
Our Technology
Immvirx logo
A clinical stage company developing novel oncolytic viruses to create powerful new cancer immunotherapy combinations
Twitter Linkedin
Company
© 2020 ImmVirX Pty Ltd • Site by Alex Shafren & Noise